EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Personalized Cancer Care: Risk Prediction, Early Diagnosis, Progression, and Therapy

Kurt S Zänker, Anne-Lise Borresen-Dale, Hans-Peter Huber

Biomedicine Hub · 2016

DOI: 10.1159/000453253 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Biomedicine Hub, 2016. Verfasst von Kurt S Zänker und 2 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Immunology and Experimental Oncology, Center for Biomedical Education and Research, University Witten/Herdecke, Witten, Germany. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

At the annual prestigious International Symposium of the Fritz-Bender Foundation, Munich, 18-20 May, 2016, researchers, clinicians, and students discussed the state of the art and future perspectives of genomic medicine in cancer. Genomic medicine (also known as precision medicine/oncology) should help clinicians to provide a more precise diagnosis and therapy in oncology for individual patients. The meeting focused on next-generation sequencing methods, analytical computational analysis of big data, and data mining on the way to translational and evidence-based medicine. The meeting covered the social and ethical impact of genomic medicine as well as news and views on antibody targeting of intracellular proteins, on the architecture of intracellular proteins and their impact on carcinogenesis, and on the adaptation of tumor therapy in due consideration of tumor evolution. Subheadings like “Genetic Profiling of Patients and Risk Prediction,” “Molecular Profiling of Tumors and Metastases,” “Tumor-Host Microenvironment Interaction and Metabolism,” and “Targeted Therapy” were subsumed under the main heading of “Personalized Cancer Care.”

Schlagwörter

Stichwörter der Autor:innen

Early diagnosisProgressionRisk predictionTherapy

Autor:innen und Institutionen

  • Institute of Immunology and Experimental Oncology, Center for Biomedical Education and Research, University Witten/Herdecke, Witten, Germany.
  • Institute for Cancer Research, The Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway.
  • Fritz-Bender Foundation, Munich, Germany.

Zitieren

APA

Zänker, K. S., Borresen-Dale, A. L., & Huber, H. P. (2016). Personalized Cancer Care: Risk Prediction, Early Diagnosis, Progression, and Therapy. Biomedicine Hub. https://doi.org/10.1159/000453253

Vancouver

Zänker KS, Borresen-Dale AL, Huber HP. Personalized Cancer Care: Risk Prediction, Early Diagnosis, Progression, and Therapy. Biomedicine Hub. 2016. doi:10.1159/000453253

BibTeX
@article{Znker2016,
  author = {Zänker, Kurt S and Borresen-Dale, Anne-Lise and Huber, Hans-Peter},
  title = {Personalized Cancer Care: Risk Prediction, Early Diagnosis, Progression, and Therapy},
  journal = {Biomedicine Hub},
  year = {2016},
  doi = {10.1159/000453253}
}
Kostenlos starten →